Literature DB >> 1622137

The induction of apoptosis by chemotherapeutic agents occurs in all phases of the cell cycle.

T G Cotter1, J M Glynn, F Echeverri, D R Green.   

Abstract

A1.1 T-cell hybridoma cells exposed to either actinomycin D (1 microgram/ml), camptothecin (200 ng/ml) or aphidicolin (10 micrograms/ml) for 16 hrs at 37 degrees C die via apoptosis. The cell death was independent of RNA synthesis, in contrast to previous data reported for other forms of apoptosis in murine lymphocyte cells and their derived lines. Each of the three agents described appeared to induce death in all phases of the cell cycle in asynchronously proliferating cells. G1 cells appeared to be more susceptible to the effects of camptothecin and contrasts with other reports which detail its selectivity for S and G2 phase cells. This might indicate that cells are progressing into S phase before dying or, alternatively, cells may indeed be dying in G1. When elutriated synchronised cells were exposed to each of the three cytotoxic agents cell death occurred in all phases of the cell cycle. In view of the fact that G1 and S phase cells did not cycle to any appreciable extent during drug exposure, it was likely that ensuing death, occurred specifically from these phases. G2/M cells, however, moved rapidly into G1 in the presence of each drug, thus making it difficult to determine whether G2/M cells were capable of undergoing drug-induced apoptosis. To overcome this problem, nocodazole (50 ng/ml) was used to block asynchronous cells in M phase. When these cells were exposed to actinomycin D, aphidicolin or camptothecin, cell death ensued via apoptosis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1622137

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  21 in total

1.  T cell receptor-induced activation and apoptosis in cycling human T cells occur throughout the cell cycle.

Authors:  M Karas; T Z Zaks; J L Liu; D LeRoith
Journal:  Mol Biol Cell       Date:  1999-12       Impact factor: 4.138

2.  The cell cycle and induction of apoptosis in a hamster fibrosarcoma cell line treated with anti-cancer drugs: its importance to solid tumour chemotherapy.

Authors:  S el Alaoui; J Lawry; M Griffin
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

Review 3.  Apoptosis: a new pharmacodynamic endpoint.

Authors:  J L Au; N Panchal; D Li; Y Gan
Journal:  Pharm Res       Date:  1997-12       Impact factor: 4.200

4.  Transformed cells require continuous activity of RNA polymerase II to resist oncogene-induced apoptosis.

Authors:  C Koumenis; A Giaccia
Journal:  Mol Cell Biol       Date:  1997-12       Impact factor: 4.272

5.  Distinction of apoptotic and necrotic cell death by in situ labelling of fragmented DNA.

Authors:  M Kressel; P Groscurth
Journal:  Cell Tissue Res       Date:  1994-12       Impact factor: 5.249

6.  Microtubule antagonists activate programmed cell death (apoptosis) in cultured rat hepatocytes.

Authors:  K Tsukidate; K Yamamoto; J W Snyder; J L Farber
Journal:  Am J Pathol       Date:  1993-09       Impact factor: 4.307

Review 7.  A potential role for apoptosis in neurodegeneration and Alzheimer's disease.

Authors:  C W Cotman; A J Anderson
Journal:  Mol Neurobiol       Date:  1995-02       Impact factor: 5.590

8.  Apoptosis in erythroid progenitors deprived of erythropoietin occurs during the G1 and S phases of the cell cycle without growth arrest or stabilization of wild-type p53.

Authors:  L L Kelley; W F Green; G G Hicks; M C Bondurant; M J Koury; H E Ruley
Journal:  Mol Cell Biol       Date:  1994-06       Impact factor: 4.272

9.  Neither macromolecular synthesis nor myc is required for cell death via the mechanism that can be controlled by Bcl-2.

Authors:  D L Vaux; I L Weissman
Journal:  Mol Cell Biol       Date:  1993-11       Impact factor: 4.272

Review 10.  Toward an understanding of the molecular mechanisms of physiological cell death.

Authors:  D L Vaux
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.